1403250-97-4

Upstream product

• 532-20-7 D-Ribose 
• 52485-92-4 methyl α-D-ribofuranoside 
• 79083-29-7 (2R,3R,4R,5S)-3,4-bis(benzyloxy)-2-((benzyloxy)methyl)-5-methoxytetrahydrofuran 
• 80795-53-5 (2S,3R,4S,5R)-4-(benzyloxy)-5-((benzyloxy)methyl)-2-methoxytetrahydrofuran-3-ol 
• 885592-69-8 (2S,4R,5R)-4-(benzyloxy)-5-((benzyloxy)methyl)-2-methoxydihydrofuran-3(2H)-one 
• 1439900-71-6 (Z)-N-((2S,4S,5R)-4-(benzyloxy)-5-((benzyloxy)methyl)-2-methoxydihydrofuran-3(2H)-ylidene)-2-methylpropane-2-sulfinamide 
• 1439900-72-7 N-((2S,3R,4S,5R)-4-(benzyloxy)-5-((benzyloxy)methyl)-2-methoxy-3-methyltetrahydrofuran-3-yl)-2-methylpropane-2-sulfinamide 
• 1439900-73-8 N-((2S,3R,4S,5R)-4-(benzyloxy)-5-((benzyloxy)methyl)-2-methoxy-3-methyltetrahydrofuran-3-yl)-2,2,2-trifluoroacetamide 
• 1439900-76-1 N-((2R,3R,4S,5R)-4-(benzyloxy)-5-((benzyloxy)methyl)-2-(2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)-3-methyltetrahydrofuran-3-yl)-2,2,2-trifluoroacetamide 
• 1439900-77-2 1-((2R,3R,4S,5R)-3-amino-4-(benzyloxy)-5-((benzyloxy)methyl)-3-methyltetrahydrofuran-2-yl)pyrimidine-2,4(1H,3H)-dione 
• 1403249-78-4 1-((2R,3R,4S,5R)-3-amino-4-hydroxy-5-(hydroxymethyl)-3-methyltetrahydrofuran-2-yl)pyrimidine-2,4(1H,3H)-dione 
• 1439900-78-3 tert-butyl ((2R,3R,4S,5R)-2-(2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)-4-hydroxy-5-(hydroxymethyl)-3-methyltetrahydrofuran-3-yl)carbamate 
• 1439900-80-7 (2S)-isopropyl 2-(((2R,3S,4R,5R)-4-((tert-butoxycarbonyl)amino)-5-(2,4-dioxo-3,4-dihydropyrimidin-1(2H)-O-3-hydroxy-4-methyltetrahydrofuran-2-ylmethoxy)(phenoxy)-phosohoryl)amino)propanoate 
• 1439900-75-0 C₂₁H₂₇NO₄ 

Relevant academic research and scientific papers

HCV Polymerase Inhibitors

The invention provides compounds of the formula: which are of use in the treatment or prophylaxis of hepatitis C virus infection, and related aspects.

HCV POLYMERASE INHIBITORS

The invention provides compounds of the formula:(I) which are of use in the treatment or prophylaxis of hepatitis C virus infection, and related aspects.